The NPPA drug price regulator has reduced the prices of anticancer drugs by almost 86% since last March to relieve patients. There has been "a significant reduction in the prices of cancer drugs since March 2016," said the National Pharmaceutical Pricing Authority (NPPA) in a tweet.
The reduction is in the price range of 86 percent to 13 percent, NPPA said. "Significant reduction in the prices of some drugs against major diabetics since March 2016," NPPA said. Prices were reduced in the range of 42 percent to 10 percent, it added.
Medications include Iressa from AstraZeneca Pharma India whose price was purchased from Rs 29,259 to Rs. 3,777, an 86 percent reduction and Grafeel from Dr. Reddy's laboratories - whose price was reduced by 41 percent, it said. While Glypride prices from Sun Pharma Laboratories Ltd were reduced by 42 percent, from Rs 91 earlier to Rs 53 after revision, other players' medicines also witnessed price reductions.
In the diabetes segment also, there has been a reduction in drug prices, said the regulator. The other pharma players the prices of which the cancer drugs have been reduced are Natco Pharma and Emcure Pharmaceuticals among others, it added. Other drugs with reduced prices include the laboratories of Dr Reddy Glimy, Obimet of Abott India, Cetapin of Sanofi India and Lupine's Gluconorm, it added.
.png)
